Highview Capital Management LLC DE Trims Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Highview Capital Management LLC DE lessened its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 69.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,155 shares of the medical research company's stock after selling 2,612 shares during the quarter. Highview Capital Management LLC DE's holdings in Thermo Fisher Scientific were worth $613,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. Citizens National Bank Trust Department grew its holdings in Thermo Fisher Scientific by 1.1% during the 4th quarter. Citizens National Bank Trust Department now owns 4,921 shares of the medical research company's stock valued at $2,612,000 after buying an additional 53 shares in the last quarter. Birch Hill Investment Advisors LLC grew its holdings in shares of Thermo Fisher Scientific by 0.4% during the fourth quarter. Birch Hill Investment Advisors LLC now owns 8,050 shares of the medical research company's stock worth $4,273,000 after purchasing an additional 30 shares in the last quarter. Essex LLC grew its holdings in shares of Thermo Fisher Scientific by 17.7% during the fourth quarter. Essex LLC now owns 731 shares of the medical research company's stock worth $388,000 after purchasing an additional 110 shares in the last quarter. Perigon Wealth Management LLC grew its holdings in shares of Thermo Fisher Scientific by 18.9% during the fourth quarter. Perigon Wealth Management LLC now owns 34,729 shares of the medical research company's stock worth $18,434,000 after purchasing an additional 5,524 shares in the last quarter. Finally, Lawson Kroeker Investment Management Inc. NE grew its holdings in shares of Thermo Fisher Scientific by 1.7% during the fourth quarter. Lawson Kroeker Investment Management Inc. NE now owns 16,855 shares of the medical research company's stock worth $8,946,000 after purchasing an additional 279 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Insider Buying and Selling

In related news, Director Debora L. Spar sold 164 shares of the company's stock in a transaction on Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the sale, the director now directly owns 1,207 shares of the company's stock, valued at $660,192.79. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total value of $5,556,300.00. Following the sale, the chief executive officer now directly owns 49,155 shares of the company's stock, valued at $27,311,992.65. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Debora L. Spar sold 164 shares of the stock in a transaction on Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the sale, the director now directly owns 1,207 shares in the company, valued at $660,192.79. The disclosure for this sale can be found here. Insiders have sold a total of 50,277 shares of company stock valued at $28,513,384 over the last ninety days. Company insiders own 0.32% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently commented on TMO shares. Citigroup started coverage on Thermo Fisher Scientific in a report on Monday, March 18th. They set a "neutral" rating and a $620.00 price objective for the company. Robert W. Baird restated an "outperform" rating and issued a $670.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, December 14th. HSBC initiated coverage on Thermo Fisher Scientific in a research report on Monday, December 18th. They issued a "buy" rating and a $610.00 target price for the company. TheStreet upgraded Thermo Fisher Scientific from a "c+" rating to a "b-" rating in a research report on Friday, December 22nd. Finally, Barclays downgraded Thermo Fisher Scientific from an "overweight" rating to an "equal weight" rating and boosted their target price for the stock from $475.00 to $555.00 in a research report on Wednesday, January 24th. Five research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $601.56.

Thermo Fisher Scientific Trading Down 1.6 %

Shares of TMO traded down $9.34 during mid-day trading on Friday, hitting $565.23. 1,194,108 shares of the company's stock traded hands, compared to its average volume of 1,553,851. The company has a quick ratio of 1.39, a current ratio of 1.75 and a debt-to-equity ratio of 0.67. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $603.82. The firm has a market capitalization of $215.75 billion, a P/E ratio of 36.65, a PEG ratio of 2.41 and a beta of 0.80. The business's 50-day moving average price is $571.39 and its 200-day moving average price is $525.37.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.64 by $0.03. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The firm had revenue of $10.89 billion for the quarter, compared to analysts' expectations of $10.73 billion. During the same period in the previous year, the firm earned $5.40 earnings per share. The business's revenue was down 4.9% compared to the same quarter last year. As a group, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, April 15th. Investors of record on Friday, March 15th will be paid a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.28%. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.35. The ex-dividend date is Thursday, March 14th. Thermo Fisher Scientific's dividend payout ratio is presently 10.10%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.